abstract: OBJECTIVE: Hyaluronidases ( @entity6 and @entity7 ) are key enzymes in the degradation of hyaluronan, and their expression has been altered in various @entity1 types. We previously showed that hyaluronan accumulation in @entity3 was correlated with decreased mRNA expression of the HYAL genes. In this study, we analyzed @entity6 and @entity7 protein expressions in normal and precancerous endometrial tissues and in @entity3 . We also investigated whether the protein levels were associated with clinicopathological factors, invasion, and disease recurrence. METHODS: A total of 343 tissue specimens from normal, @entity4 , @entity2 , and neoplastic endometria were analyzed immunohistochemically for @entity6 and @entity7 expressions. The results were correlated with clinicopathological factors, the expression of the epithelial-mesenchymal transition marker, @entity5 , and disease recurrence. RESULTS: Reduced @entity6 expression was associated with the progression of @entity3 towards higher grades and also with large @entity1 sizes, lymph node @entity0 , and @entity0 . Reduced expression of both @entity6 and @entity7 was associated with deep @entity0 . @entity7 expression was primarily constant in neoplastic tissues, but its expression was altered in different phases of the endometrial cycle. In addition, a reduction in @entity6 expression was associated with the depletion of @entity5 . In a multivariate analysis, reduced @entity6 expression was an independent prognostic factor for early disease recurrence (HR 5.13, 95% CI: 1.131-23.270, p=0.034). CONCLUSIONS: This study showed that reduced @entity6 expression was associated with @entity3 , which further supported the role of hyaluronan degradation in @entity1 progression.

title: Decreased hyaluronidase 1 expression is associated with early disease recurrence in human XXXX .

answer: @entity3


abstract: Monocytes and dendritic cells (DC) can be purified from fresh peripheral blood (PB) based on their expression of @entity2 , @entity6 , and @entity5 . Whereas DC can be identified as @entity2 + @entity5 dim or @entity6 +CD14dim cells, monocytes can be identified as @entity2 +CD14bright or @entity6 +CD14bright cells. Rheumatoid synovial fluid (SF) and synovial tissue (ST) non-T cells were found to be enriched in @entity2 +CD14dim cells compared with PB. Whereas 4 to 14% of normal or rheumatoid PB non-T cells were @entity2 + and CD14dim, in @entity0 or ST these cells comprised 20 to 45% of non-T mononuclear cells. Synovial @entity2 + @entity5 dim cells assumed a typical dendritic morphology on in vitro culture. Freshly isolated @entity2 + @entity5 dim PB DC precursors express low levels of HLA-DQ, @entity4 , and B7, which increase after in vitro incubation. In contrast, freshly isolated SF DC constitutively expressed these markers, and increased densities of HLA-DR and MHC class I molecules. Rheumatoid SF DC showed a specifically enhanced ability to stimulate autologous PB T cells compared with PB DC, or PB or SF monocytes. PB DC or monocytes preincubated in granulocyte-macrophage- @entity3 , @entity1 , or both cytokines exhibited enhanced expression of HLA-DR. Furthermore, DC preincubated in both granulocyte-macrophage- @entity3 and @entity1 were better stimulators of the autologous MLR than DC preincubated in medium, or in either cytokine alone. The data indicate that DC are enriched in @entity0 and ST, and display a more differentiated phenotype than PB DC. These results suggest that PB DC accumulate in the synovium where they undergo phenotypic and functional differentiation in situ, which may be mediated by local cytokines. DC may play an important role in the ongoing presentation of antigen to autoreactive T cells in RA synovium.

title: XXXX is enriched in mature antigen-presenting dendritic cells.

answer: @entity0


abstract: OBJECTIVE: To describe a case series of @entity0 with @entity4 evaluated in a national Spanish mutua. METHODS: Computerized medical records of 2013 were reviewed and 129 @entity0 with diagnoses compatible with @entity4 were identified. RESULTS: Eighty-six (67%) of the 129 cases were recognized as @entity2 , three cases were considered as @entity3 (two with a diagnosis of @entity1 ) and the remaining 40 cases were considered to not be work-related. Most of the cases (90%) occurred in @entity0 between the ages of 30 and 49 years. Ninety-three percent of the cases diagnosed as @entity2 underwent speech therapy and, of these, 72% were cured. The majority of the cases (61%) occurred in teachers. Average duration of sickness absence, among those @entity0 who took it, was 113.5 days. CONCLUSIONS: All cases reported as @entity2 met the criteria set by the Spanish legislation (RD 1299/2006). @entity2 were referred to the national health service. Customized speech therapy was effective for most of the @entity0 . The average duration of sick leave in our series was high.

title: [Description of XXXX cases assisted in a mutua in 2013].

answer: @entity4


abstract: BACKGROUND: Implantable left ventricular assist devices (LVADs) were designed for permanent implant, but we began their use for bridge-to-transplant (BTTx) to study their safety and effectiveness. We review our experience in order to compare the BTTx lessons learned with the outcomes and goals of permanent implants. METHODS: From December 1991 until January 2002, 264 @entity0 received 277 LVADs for BTTx. We analyzed temporal trends in pre- @entity5 @entity0 factors and device-specific time-related complications. RESULTS: Survival to transplant was 69%. Adverse event analysis demonstrated a high risk of @entity3 (0.56, 1.28, and 1.88 per @entity0 at 30 days and 3 and 6 months). HeartMate devices were more prone to @entity3 than Novacor devices (p < 0.0001). @entity4 occurred less commonly than @entity3 (0.15, 0.25, 0.30 at 30 days and 3 and 6 months), were more common in Novacor than HeartMate (p = 0.0001), and were decreased by the new Novacor Vascutek conduit (p = 0.07), but these were still slightly higher than the HeartMate (p = 0.04). @entity2 occurred in 21 instances (all but one were in HeartMate devices [p = 0.04 vs Novacor]), but have significantly decreased (p < 0.0001) in HeartMate since 1998. CONCLUSIONS: Infections and device durability limit the chronic use of the HeartMate device, but device failures are decreasing. Novacor has fewer problems with @entity3 and durability, and the new Vascutek conduit will reduce, but not eliminate, @entity1 .

title: Do @entity5 ( XXXX ) bridge-to-transplantation outcomes predict the results of permanent @entity5 implantation?

answer: @entity5


abstract: BACKGROUND: Implantable left ventricular assist devices (LVADs) were designed for permanent implant, but we began their use for bridge-to-transplant (BTTx) to study their safety and effectiveness. We review our experience in order to compare the BTTx lessons learned with the outcomes and goals of permanent implants. METHODS: From December 1991 until January 2002, 264 @entity0 received 277 LVADs for BTTx. We analyzed temporal trends in pre- @entity5 @entity0 factors and device-specific time-related complications. RESULTS: Survival to transplant was 69%. Adverse event analysis demonstrated a high risk of @entity3 (0.56, 1.28, and 1.88 per @entity0 at 30 days and 3 and 6 months). HeartMate devices were more prone to @entity3 than Novacor devices (p < 0.0001). @entity4 occurred less commonly than @entity3 (0.15, 0.25, 0.30 at 30 days and 3 and 6 months), were more common in Novacor than HeartMate (p = 0.0001), and were decreased by the new Novacor Vascutek conduit (p = 0.07), but these were still slightly higher than the HeartMate (p = 0.04). @entity2 occurred in 21 instances (all but one were in HeartMate devices [p = 0.04 vs Novacor]), but have significantly decreased (p < 0.0001) in HeartMate since 1998. CONCLUSIONS: Infections and device durability limit the chronic use of the HeartMate device, but device failures are decreasing. Novacor has fewer problems with @entity3 and durability, and the new Vascutek conduit will reduce, but not eliminate, @entity1 .

title: Do @entity5 ( @entity5 ) bridge-to-transplantation outcomes predict the results of permanent XXXX implantation?

answer: @entity5


abstract: BACKGROUND: Implantable left ventricular assist devices (LVADs) were designed for permanent implant, but we began their use for bridge-to-transplant (BTTx) to study their safety and effectiveness. We review our experience in order to compare the BTTx lessons learned with the outcomes and goals of permanent implants. METHODS: From December 1991 until January 2002, 264 @entity0 received 277 LVADs for BTTx. We analyzed temporal trends in pre- @entity5 @entity0 factors and device-specific time-related complications. RESULTS: Survival to transplant was 69%. Adverse event analysis demonstrated a high risk of @entity3 (0.56, 1.28, and 1.88 per @entity0 at 30 days and 3 and 6 months). HeartMate devices were more prone to @entity3 than Novacor devices (p < 0.0001). @entity4 occurred less commonly than @entity3 (0.15, 0.25, 0.30 at 30 days and 3 and 6 months), were more common in Novacor than HeartMate (p = 0.0001), and were decreased by the new Novacor Vascutek conduit (p = 0.07), but these were still slightly higher than the HeartMate (p = 0.04). @entity2 occurred in 21 instances (all but one were in HeartMate devices [p = 0.04 vs Novacor]), but have significantly decreased (p < 0.0001) in HeartMate since 1998. CONCLUSIONS: Infections and device durability limit the chronic use of the HeartMate device, but device failures are decreasing. Novacor has fewer problems with @entity3 and durability, and the new Vascutek conduit will reduce, but not eliminate, @entity1 .

title: Do XXXX ( @entity5 ) bridge-to-transplantation outcomes predict the results of permanent @entity5 implantation?

answer: @entity5


abstract: Local stimulation of angiogenesis is a new approach for the treatment of @entity1 . Our investigation tested intramuscular (i.m.) injection of a modified fibrin meshwork in a @entity2 model. METHODS: The left external iliac and femoral arteries were excised in 24 @entity2 that were divided into four groups: control; i.m. saline injection; fibrin meshwork plus low dose (2.5 mg) fibrinogen i.m.; fibrin meshwork plus high-dose (5.0 mg) fibrinogen i.m. Angiography was performed before surgery, immediately after surgery, and one month postoperatively. Lower limb- @entity3 blood pressure was measured immediately after surgery and at postoperative days 10, 20, and 30. On day 30, conventional indirect immunostaining was performed to determine the percentage of the area occupied by capillaries. RESULTS: Immediately after surgery, in all four groups, the number of @entity4 ( @entity4 ) crossing a specific segment of a grid decreased from 5.3 +/- 1.3 to 3.2 +/- 1.0 (p < 0.05); the number of grid intersections decreased from 30.2 +/- 6.5 to 19.3 +/- 4.8 (p < 0.05); and the total number of grids with @entity4 decreased from 18.3 +/- 3.8 to 12.2 +/- 2.5 (p < 0.05). One month after surgery, in the control group, these parameters were 6.2 +/- 1.1, 33.2 +/- 5.7 and 20.3 +/- 1.5, respectively; in the saline-treated group, these parameters were 6.1 +/- 0.8, 28.3 +/- 6.9 and 19.8 +/- 1.1, respectively (p > 0.05 versus control and versus baseline data). When fibrin containing 5.0 mg fibrinogen was used, these parameters increased to 8.5 +/- 0.9, 48.3 +/- 5.1, and 27.1 +/- 0.9, respectively (p < 0.001 versus immediately after surgery and p < 0.05 versus control). In all four series, no Doppler flow signal was detected from the posterior tibial artery by day 10. By day 30, the lower limb- @entity3 blood pressure ratio had improved in all four series, but was significantly improved in only the two groups treated with fibrin sealant (0.3 +/- 0.05 control; 0.3 +/- 0.08 saline; 0.6 +/- 0.06 fibrinogen 2.5; 0.7 +/- 0.05 fibrinogen 5.0). CONCLUSION: Intramuscular injection of a fibrin meshwork considerably increased angiogenesis in the severely @entity1 hind limb and may be strongly recommended for clinical use in @entity0 with limb-threatening @entity1 .

title: Direct fibrin injection to promote new collateral growth in hind limb @entity1 in a XXXX model.

answer: @entity2


abstract: Local stimulation of angiogenesis is a new approach for the treatment of @entity1 . Our investigation tested intramuscular (i.m.) injection of a modified fibrin meshwork in a @entity2 model. METHODS: The left external iliac and femoral arteries were excised in 24 @entity2 that were divided into four groups: control; i.m. saline injection; fibrin meshwork plus low dose (2.5 mg) fibrinogen i.m.; fibrin meshwork plus high-dose (5.0 mg) fibrinogen i.m. Angiography was performed before surgery, immediately after surgery, and one month postoperatively. Lower limb- @entity3 blood pressure was measured immediately after surgery and at postoperative days 10, 20, and 30. On day 30, conventional indirect immunostaining was performed to determine the percentage of the area occupied by capillaries. RESULTS: Immediately after surgery, in all four groups, the number of @entity4 ( @entity4 ) crossing a specific segment of a grid decreased from 5.3 +/- 1.3 to 3.2 +/- 1.0 (p < 0.05); the number of grid intersections decreased from 30.2 +/- 6.5 to 19.3 +/- 4.8 (p < 0.05); and the total number of grids with @entity4 decreased from 18.3 +/- 3.8 to 12.2 +/- 2.5 (p < 0.05). One month after surgery, in the control group, these parameters were 6.2 +/- 1.1, 33.2 +/- 5.7 and 20.3 +/- 1.5, respectively; in the saline-treated group, these parameters were 6.1 +/- 0.8, 28.3 +/- 6.9 and 19.8 +/- 1.1, respectively (p > 0.05 versus control and versus baseline data). When fibrin containing 5.0 mg fibrinogen was used, these parameters increased to 8.5 +/- 0.9, 48.3 +/- 5.1, and 27.1 +/- 0.9, respectively (p < 0.001 versus immediately after surgery and p < 0.05 versus control). In all four series, no Doppler flow signal was detected from the posterior tibial artery by day 10. By day 30, the lower limb- @entity3 blood pressure ratio had improved in all four series, but was significantly improved in only the two groups treated with fibrin sealant (0.3 +/- 0.05 control; 0.3 +/- 0.08 saline; 0.6 +/- 0.06 fibrinogen 2.5; 0.7 +/- 0.05 fibrinogen 5.0). CONCLUSION: Intramuscular injection of a fibrin meshwork considerably increased angiogenesis in the severely @entity1 hind limb and may be strongly recommended for clinical use in @entity0 with limb-threatening @entity1 .

title: Direct fibrin injection to promote new collateral growth in hind limb XXXX in a @entity2 model.

answer: @entity1


abstract: BACKGROUND: Anal @entity1 is a common and multifactorial pathology that affects @entity0 ' lives and imposes considerable socioeconomic consequences. OBJECTIVE: The aim of this study is to evaluate the efficacy of a bulking agent, polyacrylate-polyalcohol (PP), in terms of diminishing the severity of @entity1 and improving the @entity0 's quality of life, assessing any adverse events. DESIGN: Data were obtained through a prospective, nonconsecutive, multicenter, noncomparative, postmarket study with a maximum expected follow-up of 3 years. Four investigational centers from Argentina and Brazil participated in this study. SETTINGS: Injections of the bulking agent were administered in the operating room of tertiary hospitals. @entity0 : Fifty-eight @entity0 were enrolled. Five @entity0 were lost to follow-up. Of the remaining 53 @entity0 , 41 (77.4%) were females. All @entity0 scored between 6 and 12 on the Cleveland Clinic Florida-Fecal Incontinence Score as part of the inclusion criteria. INTERVENTIONS: The injection of the bulking agent (PP) was administered under intravenous sedation in the submucosa of the anal canal through the perianal skin to generate a bulk. MAIN OUTCOME MEASURES: The primary efficacy end point was the Cleveland Clinic Florida-Fecal Incontinence Score (or Jorge and Wexner index). The Rockwood-Fecal Incontinence Quality of Life index was also recorded. The treatment was considered successful if @entity0 achieved a postoperative improvement of at least 50% on the Cleveland Clinic Florida-Fecal Incontinence Score. RESULTS: Successful treatment was met by 60.4% of the @entity0 according to the last follow-up data. Quality-of-life indices showed consistently significant improvements. LIMITATIONS: Selection bias and the lack of a control group to evaluate the potential placebo effect of this novel bulking agent were limitations of this study. Because of the eligibility criteria, the resulting @entity0 sample is representative of only a limited portion of the population with @entity2 at all 4 centers involved in this study. CONCLUSIONS: The injection technique was easy to perform, safe, and ideal for use as an outpatient procedure. This bulking agent (PP) significantly improved continence and quality of life in selected @entity0 .

title: Initial results of a new bulking agent for XXXX : a multicenter study.

answer: @entity2


abstract: UNASSIGNED: Background: Standard care for initiation of enteral feeding in @entity0 has been pull percutaneous endoscopic gastrostomy (pull- @entity2 ). As an alternative to pull- @entity2 , a 1-step endoscopic procedure for inserting a @entity1 "button" has been developed that allows initial placement of a balloon-retained device. This report presents outcomes of metrics used to compare button placement with pull- @entity2 in a pediatric population. Methods: Data were generated from procedural experiences of surgeons on pediatric @entity0 (n = 374) with a variety of clinical indications for gastrostomy. Study population ages ranged from 6 days to 16 years, while weights were from 2-84 kg. Results: The button was successfully placed by the 1-step procedure in 98% of the respective study population, and median procedural times were 20 and 15 minutes for button and pull- @entity2 placements, respectively. Median times to first feeds were equivalent for the 1-step procedure and pull- @entity2 (6 hours), while times to first nutrition feeds were 12.5 and 10 hours, respectively. Stoma site complications within each study group were similar. Healthy stoma proportions were 65.2% and 73.2% in the 1-step procedure and pull- @entity2 groups, respectively, at first follow-up. Conclusions: Similar study outcomes between the 1-step procedure and pull- @entity2 groups suggest that the former is a feasible alternative to pull- @entity2 for initial tube placement in @entity0 . The 1-step method involves a single procedure and reduces @entity0 exposure to anesthesia, operating room time, and the potential for complications compared with a pull- @entity2 requirement for multiple procedures.

title: One-Step Insertion of Low-Profile Gastrostomy in Pediatric XXXX vs Pull Percutaneous Endoscopic Gastrostomy: Retrospective Analysis of Outcomes.

answer: @entity0


abstract: Alternating non-cross-resistant chemotherapy has been induced for the treatment of @entity3 ( @entity3 ) with the aim of cure, even in advanced cases. We formulated a new high dose regimen, CAMBO-VIP, which was a weekly treatment. They were administered during alternate weeks for a total period of 12 weeks. We obtained high response rate and prolonged disease-free survival with this regimen. We noticed the elevation of serum LDH level in some @entity0 at or shortly after the completion of CAMBO-VIP treatment. LDH elevation was not associated with liver function abnormality in terms of elevation of GOT or total @entity2 . All of these @entity0 were in complete or partial response with no evidence of @entity1 progression. An LDH isozyme study which was done at the time of LDH elevation showed elevation of both LDH1 and LDH2. Interestingly serum @entity4 was undetectable in all 6 @entity0 measured at the time of LDH elevation. @entity5 and leukoerythroblastosis in peripheral blood were also observed in all of these @entity0 . These abnormalities including LDH elevation returned to normal within a rather short period, usually within 1 to 3 weeks. From these observations, it is most likely that these abnormalities were due to excessive blood cell destruction, which was observed in association with rapid recovery from myelosuppression.

title: [Increased blood cell destruction during vigorous regeneration of bone marrow after CAMBO-VIP chemotherapy for XXXX ].

answer: @entity3


abstract: UNASSIGNED: The @entity0 ( @entity0 ) protein plays an important role in the repair of DNA double-strand breaks. The relationship between @entity0 polymorphisms and the risk of radiation-induced @entity3 on normal tissue remains inconclusive. Thus, we performed a meta-analysis to elucidate the association between @entity0 polymorphisms and radiation-induced @entity3 on normal tissue. All eligible studies up to December 2014 were identified through a search of the PubMed, Embase and Web of Science databases. Seventeen studies involving 656 cases and 2193 controls were ultimately included in this meta-analysis. The pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the association between @entity0 polymorphisms and the risk of radiation-induced normal tissue @entity3 . We found that the @entity0 @entity2 ( @entity1 ) polymorphism was significantly associated with early @entity3 induced by radiotherapy (OR = 1.99, 95%CI: 1.31-3.01, P = 0.001). A positive association lacking statistical significance with late @entity3 was also identified (OR = 1.28, 95%CI: 0.97-1.68, P = 0.08). In addition, the @entity1 polymorphism was significantly correlated with a higher risk of @entity3 induced by head and neck area irradiation (OR = 2.41, 95%CI: 1.49-3.89, p = 0.0003) and breast irradiation (OR = 1.41, 95%CI: 1.02-1.95, p = 0.04), whereas the correlation was not significant for lung irradiation or pelvic irradiation. Furthermore, @entity0 @entity4 polymorphism may have a protective effect against late @entity3 induced by radiotherapy (OR = 0.47, 95%CI: 0.26-0.86, P = 0.01). Well-designed large-scale clinical studies are required to further validate our results.

title: Association between Single Nucleotide Polymorphisms in XXXX and Radiation-Induced Adverse Effects on Normal Tissue: A Meta-Analysis.

answer: @entity0


abstract: OBJECTIVE: @entity0 with glucocorticoid excess have increased cardiovascular risk, decreased bone mineral density and impaired quality of life (QoL). The aim of this study was to evaluate the association between urinary @entity2 excretion and cardiovascular risk factors, bone status and QoL in the population. We hypothesized that higher @entity2 excretion was associated with adverse cardiovascular risk profile, worse skeletal health and QoL. DESIGN, @entity0 AND METHODS: This was a cross-sectional study including a population sample (n=348), aged 38-77years. The mean age in @entity0 was 64.0  8.5years (n=276) and 60.3  10.2years in @entity0 (n=72). The @entity1 , body composition measured with bioimpedance, calcaneal quantitative ultrasound, fractures and QoL evaluated with the Nottingham Health Profile, Psychological General Well-Being (PGWB) and the Short Form 36 (SF-36) were studied. Urinary free @entity2 (UFC) was measured using radioimmunoassay. RESULTS: UFC was higher in @entity0 (230  120nmol/L) compared to @entity0 (153  71; P<0.001) and decreased with increasing age (P<0.001). In a regression analysis, after adjustment for gender, age and body mass index, higher UFC was associated with higher fat-free mass (P<0.01), favourable calcaneal bone measurements (P<0.05), better general health measured with PGWB (P<0.01) and SF-36 (P=0.001) and tended to be negatively associated with the @entity1 (P=0.07). CONCLUSION: In contrast to our hypothesis, UFC in the upper physiological range was associated with a favourable cardiovascular risk profile, bone measures and QoL.

title: The association between urinary XXXX excretion and cardiovascular risk factors, bone status and quality of life in the population.

answer: @entity2


abstract: @entity7 is a local complication of @entity0 @entity3 . It is defined as the triad of advanced @entity3 , medical thinning and aortic adventitial @entity1 . It is present to a variable degree in association with @entity4 . These aortic adventitial infiltrates differ from those described solely within the @entity5 itself, in that they consist predominantly of B lymphocytes. Many of the lymphocytes are activated and proliferating, and germinal centres are common. In this study, an immunohistochemical analysis was carried out on fresh surgical @entity2 tissue in order to investigate the presence and distribution of activation-inducible adhesion molecules, and to correlate this with the degree of @entity1 . A consistent finding was the presence of @entity8 on endothelial cells in up to 50% of the vessels throughout the aortic wall and at the base of the @entity5 , independent of the severity of @entity1 . @entity6 expression was abundant on many cell types and increased with the severity of @entity1 , being strongest in the germinal centres. @entity9 expression was predominant on follicular dendritic cells and also increased with severity of @entity1 . @entity9 expression was also detected on vessels within lymphoid follicles. The pattern of expression of the adhesion molecules suggests a role in the initiation and progression of @entity1 associated with advanced @entity3 .

title: The distribution of adhesion molecules in chronic XXXX .

answer: @entity7


abstract: UNASSIGNED: Pulmonary neutrophil infiltration produced by Staphylococcal enterotoxin A (SEA) airway exposure is accompanied by marked granulocyte accumulation in bone marrow (BM). Therefore, the aim of this study was to investigate the mechanisms of BM cell accumulation, and trafficking to circulating blood and lung tissue after SEA airway exposure. Male BALB/C @entity0 were intranasally exposed to SEA (1 g), and at 4, 12 and 24h thereafter, BM, circulating blood, bronchoalveolar lavage (BAL) fluid and lung tissue were collected. Adhesion of BM granulocytes and flow cytometry for @entity6 , @entity7 and VLA-4 and cytokine and/or chemokine levels were assayed after SEA-airway exposure. Prior exposure to SEA promoted a marked PMN influx to BAL and lung tissue, which was accompanied by increased counts of immature and/or mature neutrophils and eosinophils in BM, along with blood neutrophilia. Airway exposure to SEA enhanced BM neutrophil @entity6 expression, and adhesion to @entity8 and/or @entity9 -coated plates. Elevated levels of @entity5 , @entity10 , INF-y, @entity2 , KC/ @entity11 and SDF-1a were detected in BM after SEA exposure. SEA exposure increased production of eosinopoietic cytokines ( @entity3 and @entity1 ) and BM eosinophil VLA-4 expression, but it failed to affect eosinophil adhesion to @entity8 and @entity9 . In conclusion, BM neutrophil accumulation after SEA exposure takes place by integrated action of cytokines and/or chemokines, enhancing the adhesive responses of BM neutrophils and its trafficking to lung tissues, leading to @entity4 . BM eosinophil accumulation in SEA-induced @entity4 may occur via increased eosinopoietic cytokines and VLA-4 expression.

title: Staphylococcal enterotoxin A regulates bone marrow granulocyte trafficking during pulmonary inflammatory disease in XXXX .

answer: @entity0


abstract: Successful surgical treatment of @entity2 requires the localization and excision of the parathyroid tissue responsible for excessive @entity3 secretion while ensuring that the @entity0 will have sufficient endogenous @entity3 production to maintain eucalcemia. In selecting @entity0 with @entity2 for unilateral parathyroidectomy the surgeon should be able to diagnose @entity1 either preoperatively or intraoperatively. We performed a retrospective review of 123 @entity0 who underwent surgical treatment for @entity2 to determine the potential feasibility of selecting @entity0 for minimally invasive surgery based on preoperative imaging studies. All @entity0 were studied preoperatively with 99m technetium-sestamibi scintigraphy. High-resolution ultrasonography was performed in 119 of these @entity0 . All @entity0 except one underwent bilateral cervical exploration. A @entity0 with an intrathoracic @entity4 was successfully diagnosed by scintigraphy thereby allowing treatment by a limited thoracotomy. One hundred eight @entity0 had solitary @entity4 and 15 had @entity1 . In none of the @entity0 with bilateral @entity1 were all abnormal glands localized preoperatively. @entity0 in our study with primary @entity5 were underdiagnosed by preoperative imaging. A minimally invasive approach based solely on preoperative imaging studies may result in treatment failure in @entity0 with multiglandular involvement.

title: Limitations of technetium 99m sestamibi scintigraphic localization for XXXX associated with @entity1 .

answer: @entity2


abstract: Successful surgical treatment of @entity2 requires the localization and excision of the parathyroid tissue responsible for excessive @entity3 secretion while ensuring that the @entity0 will have sufficient endogenous @entity3 production to maintain eucalcemia. In selecting @entity0 with @entity2 for unilateral parathyroidectomy the surgeon should be able to diagnose @entity1 either preoperatively or intraoperatively. We performed a retrospective review of 123 @entity0 who underwent surgical treatment for @entity2 to determine the potential feasibility of selecting @entity0 for minimally invasive surgery based on preoperative imaging studies. All @entity0 were studied preoperatively with 99m technetium-sestamibi scintigraphy. High-resolution ultrasonography was performed in 119 of these @entity0 . All @entity0 except one underwent bilateral cervical exploration. A @entity0 with an intrathoracic @entity4 was successfully diagnosed by scintigraphy thereby allowing treatment by a limited thoracotomy. One hundred eight @entity0 had solitary @entity4 and 15 had @entity1 . In none of the @entity0 with bilateral @entity1 were all abnormal glands localized preoperatively. @entity0 in our study with primary @entity5 were underdiagnosed by preoperative imaging. A minimally invasive approach based solely on preoperative imaging studies may result in treatment failure in @entity0 with multiglandular involvement.

title: Limitations of technetium 99m sestamibi scintigraphic localization for @entity2 associated with XXXX .

answer: @entity1


abstract: BACKGROUND: Recent trials involving pirfenidone suggest a beneficial effect in the treatment of @entity1 ( @entity1 ). OBJECTIVE: To report on the efficacy and safety of pirfenidone in the treatment of @entity0 with @entity1 , at a tertiary care hospital in Saudi Arabia. METHODS: The study included 58 @entity0 with @entity1 who were evaluated from March 2012 to March 2013. During the study period, 33 @entity0 received pirfenidone, and the remaining @entity0 (n = 25) served as a control group. Baseline clinical characteristics, physiological parameters and the results of a 36-Item Short Form Health Survey (SF-36) were compared between the groups. Furthermore, we compared changes in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLco), six-minute walk distance (6MWD) and SF-36 for both groups during follow-up. The last follow-up period ended in January 2014. RESULTS: There were no significant differences in baseline clinical characteristics between the groups. Furthermore, we found no differences in FVC, DLco and SF-36 during follow-up (median, 12 months). However, @entity0 receiving pirfenidone treatment were less likely to experience reductions in 6MWD compared with the control group (13% vs. 52%, respectively; P = 0.001). Although adverse events were more frequently reported by the pirfenidone group compared with the control group (85 vs. 56%, respectively; P = 0.015), these @entity0 did not require discontinuation of treatment. CONCLUSION: Pirfenidone treatment preserves functional capacity, as reflected by the 6MWD. Adverse events associated with pirfenidone treatment were generally well tolerated by the @entity0 .

title: Pirfenidone treatment in XXXX : A Saudi experience.

answer: @entity1


abstract: BACKGROUND: Data on the safety of @entity2 and @entity4 during pregnancy are very sparse. AIM: To examine the risk of adverse birth outcomes in @entity0 who took up prescriptions for @entity2 or @entity4 during pregnancy. METHODS: This is a Danish cohort study based on data from a population-based prescription registry, the Danish Birth Registry and the Hospital Discharge Registry. To examine the risk of @entity3 , we included nine pregnancies exposed 30 days before conception or during the first trimester. To examine perinatal mortality, pre-term birth and low birth weight, we included 10 pregnancies exposed during the entire pregnancy. Eleven different exposed @entity0 were included in the study. Outcomes were compared with those of 19 418 pregnancies in which no drugs were prescribed to the mothers. RESULTS: Fifty-five per cent of the exposed @entity0 had @entity1 and 45% other diseases. Adjusted odds ratios for @entity3 , perinatal mortality, pre-term birth and low birth weight were 6.7 (95% confidence interval, 1.4-32.4), 20.0 (2.5-161.4), 6.6 (1.7-25.9) and 3.8 (0.4-33.3), respectively. CONCLUSIONS: Our results suggest that there is an increased risk of @entity3 , perinatal mortality and pre-term birth in @entity0 born to @entity0 treated with @entity2 or @entity4 during pregnancy. More data are needed to determine whether the associations are causal or occur through confounding.

title: @entity2 , XXXX and birth outcome: a population-based cohort study.

answer: @entity4


abstract: BACKGROUND: Data on the safety of @entity2 and @entity4 during pregnancy are very sparse. AIM: To examine the risk of adverse birth outcomes in @entity0 who took up prescriptions for @entity2 or @entity4 during pregnancy. METHODS: This is a Danish cohort study based on data from a population-based prescription registry, the Danish Birth Registry and the Hospital Discharge Registry. To examine the risk of @entity3 , we included nine pregnancies exposed 30 days before conception or during the first trimester. To examine perinatal mortality, pre-term birth and low birth weight, we included 10 pregnancies exposed during the entire pregnancy. Eleven different exposed @entity0 were included in the study. Outcomes were compared with those of 19 418 pregnancies in which no drugs were prescribed to the mothers. RESULTS: Fifty-five per cent of the exposed @entity0 had @entity1 and 45% other diseases. Adjusted odds ratios for @entity3 , perinatal mortality, pre-term birth and low birth weight were 6.7 (95% confidence interval, 1.4-32.4), 20.0 (2.5-161.4), 6.6 (1.7-25.9) and 3.8 (0.4-33.3), respectively. CONCLUSIONS: Our results suggest that there is an increased risk of @entity3 , perinatal mortality and pre-term birth in @entity0 born to @entity0 treated with @entity2 or @entity4 during pregnancy. More data are needed to determine whether the associations are causal or occur through confounding.

title: XXXX , @entity4 and birth outcome: a population-based cohort study.

answer: @entity2


abstract: This is a prospective and nonrandomized study in which 86 @entity0 with previously untreated @entity3 ( @entity3 ) were clinically staged (CS) and treated with chemotherapy (CT) alone. Fifty-two (CS IA-38, IIA-7, IIB-3, IIIA-4) received six courses of @entity2 , @entity9 , @entity8 , and @entity1 (CVPP). Ten (CS IA with peripheral nodes) received only three courses of CVPP with a reinforcement of C on day 8. Twenty-four (CS IIIB-18, @entity7 , IVB-4) received six courses of CVPP alternating with six courses of @entity4 , @entity5 , and @entity6 (EBO). Surgical staging was not performed in any @entity0 . Two @entity0 (CS IIIB) had partial remission and died from progressive disease. Seventy out of 86 @entity0 have not relapsed and are in complete remission with a median follow-up of 65 months (range 13-156 months); 14 @entity0 relapsed seven to 37 months from diagnosis (median 16 months); one of them (IV B) died of disease. Thirteen are in second and third remission (median 55 months). Actuarial five year survival rates and relapse-free survival rates are 100% and 90% for CS I to IIIA and 81% and 60% for CS IIIB and IV, respectively. As a result of this study, we can conclude that in developing countries most of the @entity0 with @entity3 staged by noninvasive diagnostic techniques can be cured with CT alone as primary treatment and thus will not suffer from the late effects of radiotherapy (RT) and the morbidity of laparotomy and splenectomy. RT alone or with other CT combinations should be considered for @entity0 who develop relapse of @entity3 .

title: XXXX in Costa Rica: twelve years' experience of primary treatment by chemotherapy alone, without staging laparotomy.

answer: @entity3


abstract: BACKGROUND: Acupuncture has recently received considerable attention around the world due to its cost-effectiveness, few side effects, and well-established analgesic properties. OBJECTIVES: The present study aimed to identify the factors that might lead to using acupuncture for @entity1 relief. @entity0 AND METHODS: This qualitative study was conducted using conventional content analysis method. The study population included eight @entity0 and six highly experienced acupuncturists, who were able to express their opinion and were willing to take part in the study. The inclusion criteria for @entity0 were being under treatment with acupuncture for @entity1 relief or a history of treatment during the last year and age > 18 years. All highly trained acupuncturists with minimum of one-year active experience were included. The data were collected via semi-structured in-depth interviews. Categories were extracted through inductive analysis and codes and eventually, themes emerged. Data rigor was assured by data collection triangulation, @entity0 ' variety, and external and members' check. RESULTS: Initially, 1311 primary codes were extracted, then the related codes were divided into 127 subcategories according to their similarities, and after reduction and integration process, 16 categories were developed from subcategories and eventually five themes were determined, including conventional medicine limitation, efficacy of acupuncture, external promoters, internal promoters, and acupuncture inhibitors. CONCLUSIONS: The important factors that affect choosing acupuncture for @entity1 relief included conventional medicine limitations, external promoters, internal promoters, acupuncture efficacy, and acupuncture inhibitors. More interest can be drawn to this technique by basic planning to enhance some of the underlying factors and eliminate obstacles to its further applicability.

title: The reasons for using acupuncture for XXXX relief.

answer: @entity1


abstract: OBJECTIVES: To substantiate reports of increasing proportions of @entity3 of diffuse histologic type and in the proximal portion of the stomach, to better understand the prognostic features that govern survival, and to determine whether alterations of operative strategy might improve the surgical results. DESIGN: Retrospective analysis of 289 consecutive @entity0 with @entity3 operated on by general surgeons over a 26-year period. Records were reviewed for location, histologic type, resection, operative mortality, lymph node status, and outcome. SETTING: The Section of Surgical Oncology, the New England Deaconess Hospital, Boston, Mass. MAIN OUTCOME MEASURES: Survival rate, length of life of the @entity0 who died, and operative mortality. RESULTS: A marked and significant shift of @entity3 to a proximal location (54% between 1985 and 1990) occurred over 26 years (P = .0075) with a significant stage improvement at presentation (P = .0235). Percentages of @entity2 that were of the diffuse, poorly differentiated histologic type increased to 48%. More curative operations were performed in the last period (61%), and this upward trend from 37% was significant. Proximal @entity3 had a poorer prognosis with more operative deaths, more lymph node @entity1 , and worse survival rates than @entity2 . Poor survival rates occurred even when comparing @entity0 with negative lymph nodes or favorable histologic features with @entity0 with similar @entity2 . CONCLUSIONS: Despite significant increases in the proportion of proximal @entity2 , survival rates have improved only slightly. Nodal status plays a less prognostic role than does location or histologic type but does provide prognostic information for individual locations. Survival rates for diffuse histologic @entity2 were consistently worse than those for intestinal histologic @entity2 , which emphasizes the underlying disease biology controlling outcome. Radical lymphadenectomy for @entity3 would not improve surgical outcome in the United States.

title: Shifting proportions of XXXX .

answer: @entity3


abstract: BACKGROUND: Antiangiogenic substances and @entity7 ( @entity7 ) may have synergistic effects and improve irradiation efficacy. We present a cohort study evaluating the @entity4 of combined @entity8 and @entity7 as neoadjuvant treatment of extremity and @entity5 (STS). METHODS: Sixteen @entity0 with locally advanced extremity (6/16) or retroperitoneal (10/16) STS were treated with continuous-dosing @entity8 (15/16: 37.5  mg daily; 1/16: 25  mg daily) and standard @entity7 (45-50.4  Gy) preoperatively. Surgery was scheduled 5-9  weeks following neoadjuvant treatment. The primary goal of the study was to determine combined treatment @entity4 according to the Common Terminology Criteria for Adverse Events. Secondary goals were the evaluation of postoperative morbidity and treatment response. RESULTS: Eight of 16 @entity0 developed grade 3, and one @entity0 developed grade 4, hematological @entity4 . One @entity0 experienced grade 3 @entity9 . The most frequent treatment toxicities of any grade were hematological (15/16) or dermatological (9/16). Three @entity0 had partial response, 11 had stable disease, and 2 had progressive disease according to Response Evaluation Criteria in @entity2 (RECIST). Fourteen of 16 @entity0 underwent surgery; @entity2 were not removed in two @entity0 because of @entity0 refusal or intercurrent @entity1 . The proportion of @entity2 @entity3 exceeded 90  % in 5 of 14 @entity0 , and 4 @entity0 had @entity6 requiring reintervention. CONCLUSIONS: Preoperative treatment with concurrent @entity8 and @entity7 was tolerable, and postoperative morbidity did not increase. Combined treatment with @entity7 and @entity8 was also feasible in @entity0 with retroperitoneal STS, and warrants further investigation.

title: Combined Radiation Therapy and @entity8 for Preoperative Treatment of Soft Tissue XXXX .

answer: @entity5


abstract: BACKGROUND: Antiangiogenic substances and @entity7 ( @entity7 ) may have synergistic effects and improve irradiation efficacy. We present a cohort study evaluating the @entity4 of combined @entity8 and @entity7 as neoadjuvant treatment of extremity and @entity5 (STS). METHODS: Sixteen @entity0 with locally advanced extremity (6/16) or retroperitoneal (10/16) STS were treated with continuous-dosing @entity8 (15/16: 37.5  mg daily; 1/16: 25  mg daily) and standard @entity7 (45-50.4  Gy) preoperatively. Surgery was scheduled 5-9  weeks following neoadjuvant treatment. The primary goal of the study was to determine combined treatment @entity4 according to the Common Terminology Criteria for Adverse Events. Secondary goals were the evaluation of postoperative morbidity and treatment response. RESULTS: Eight of 16 @entity0 developed grade 3, and one @entity0 developed grade 4, hematological @entity4 . One @entity0 experienced grade 3 @entity9 . The most frequent treatment toxicities of any grade were hematological (15/16) or dermatological (9/16). Three @entity0 had partial response, 11 had stable disease, and 2 had progressive disease according to Response Evaluation Criteria in @entity2 (RECIST). Fourteen of 16 @entity0 underwent surgery; @entity2 were not removed in two @entity0 because of @entity0 refusal or intercurrent @entity1 . The proportion of @entity2 @entity3 exceeded 90  % in 5 of 14 @entity0 , and 4 @entity0 had @entity6 requiring reintervention. CONCLUSIONS: Preoperative treatment with concurrent @entity8 and @entity7 was tolerable, and postoperative morbidity did not increase. Combined treatment with @entity7 and @entity8 was also feasible in @entity0 with retroperitoneal STS, and warrants further investigation.

title: Combined Radiation Therapy and XXXX for Preoperative Treatment of Soft Tissue @entity5 .

answer: @entity8


abstract: @entity0 in a private practice, evaluated for prostatism due to @entity1 were offered the options of medical treatment with the alpha blocker @entity3 , surgical treatment, or continued observation. Nineteen @entity0 accepted @entity3 treatment and are the subjects of the present series. They were treated over a mean period of 8 months, the longest treatment lasting over 22 months. Dosage was started at 1 mg/d and increased as tolerated to 2, 5, and 10 mg/d over the test period. Extensive testing including invasive urodynamics, multiple voiding diaries, and symptoms scores at each dosage level was carried out. We found that flow rates increased moderately from baseline in a dose dependent fashion. At the 10 mg/d dosage some @entity0 achieved flow rates in the low normal range. @entity0 on treatment documented a decrease in the number of voidings per day, a decrease in @entity2 , an increase in bladder capacity and the volume of each voiding. On the other hand, @entity0 frequently did not appreciate changes in their voiding patterns, as reflected in their responses to the symptom questionnaires. We could not demonstrate significant changes in bladder pressures on cystometry either during filling or voiding. Our data suggested that @entity3 may well have a direct effect on the fundus of the aging bladder to increase capacity, and, through the well-known relationship between voided volume and flow rate, increase urinary flow rate.

title: Effect of XXXX on urine storage and voiding in the aging male with prostatism.

answer: @entity3


abstract: @entity2 producing cells at the bone-implant interface obtained during revision of loosened total joint replacements were demonstrated by immunohistochemistry on tissue sections. Other markers for the characterization of macrophages, B cells, T cell subpopulations, @entity4 and HLA-DR antigens were also used. The 10 cases examined showed excessive metallosis within the cytoplasm of the macrophages and extracellular matrix. @entity2 containing cells were found in seven cases, four of which showed positive staining on more than 80% of the macrophages. A relatively similar proportion of T cells was seen in all the cases. T helper ( @entity0 positive) cells were always present in excess of T suppressor ( @entity1 positive) subtype. T cells showed no expression of detectable membrane @entity4 . No B cells were found in these cases. Macrophages showed very strong immunostaining for HLA-DR. These findings indicate the possible induction of @entity2 production by activated macrophages in the interface in response to the presence of metallic wear debris. In view of the well known effect of @entity2 as a potent mediator of bone lysis, the results suggest a major role of the metal debris-containing macrophages in the process of @entity3 and subsequent implant loosening.

title: Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: a potential role in XXXX .

answer: @entity3


abstract: BACKGROUND: A possible etiological association between @entity2 and @entity1 has been repeatedly reported in the literature. OBJECTIVE: Our aim was to evaluate published epidemiological data on this issue. REVIEW METHODS: We conducted an extensive search of the literature in MEDLINE, of articles ever published until February 2014, using the key-words " @entity2 " and "ovarian" and one of the following terms in the title: " @entity0 " or " @entity0 " or " @entity0 " or "transformation." Retrieved papers were checked for further relevant publications. RESULTS: Overall, our search yielded 1 prospective cohort study, 10 retrospective cohort, and 5 case-control studies. A meta-analysis of these studies was not considered to be appropriate, due to differences in data reporting, study design, and adjustment for confounding factors. LIMITATIONS: The main limitation of studies found, with one exception, was the lack of operative confirmation of @entity2 . CONCLUSION: An association of @entity2 with @entity1 was a consistent finding in most studies. On the other hand, existing epidemiological evidence linking @entity2 with @entity1 is insufficient to change current clinical practice. Prospective cohort studies, with prior laparoscopic confirmation, localization, and staging of @entity2 are needed, in order to further clarify this issue.

title: Endometriosis and XXXX risk: a systematic review of epidemiological studies.

answer: @entity1


abstract: BACKGROUND: There is no gold standard technique for @entity2 ( @entity2 ) repair. Conventional open @entity2 repair often produces an undesirable scar. Laparoscopic @entity2 repair requires multiple incisions beyond the umbilicus, specialized equipments, and expensive tissue separating mesh. We describe our technique of open @entity2 repair utilizing a small incision. The technique was derived from our experience with single incision laparoscopy. We report the technical details and short-term results. METHODS: This is a retrospective analysis of the first 20 @entity0 , who underwent minimal incision scar-less open @entity2 repair, from June 2011 to February 2014. A single intra-umbilical curved incision was used to gain access to the @entity1 sac. Primary suture repair was performed for defects up to 2   cm. Larger defects were repaired using an onlay mesh. In @entity0 with a BMI of 30   kg/m(2) or greater, onlay mesh hernioplasty was performed irrespective of the defect size. RESULTS: A total of 20 @entity0 , 12 males and 8 females underwent the procedure. Mean age was 50 (range 29-82) years. Mean BMI was 26.27 (range 20.0-33.1) kg/m(2). Average size of the incision was 1.96 range (1.5-2.5) cm. Mesh hernioplasty was done in nine @entity0 . Eleven @entity0 underwent primary suture repair alone. There were no postoperative complications associated with this technique. Average postoperative length of hospital stay was 3.9 (range 2-10) days. Mean follow-up was 29.94   months (2   weeks to 2.78   years). On follow-up there was no externally visible scar in any of the @entity0 . There were no recurrences on final follow-up. CONCLUSION: This technique provides a similar cosmetic effect as obtained from single port laparoscopy. It is easy to perform, safe, offers good cosmesis, does not require incisions beyond the umbilicus, and cost effective, with encouraging results on short-term follow-up. Further research is needed to assess the true potential of the technique and the long-term results.

title: Minimal incision scar-less open XXXX repair in adults - technical aspects and short-term results.

answer: @entity2


abstract: BACKGROUND: Evidence guiding adjuvant chemotherapy (AC) use after lobectomy for stage I @entity2 ( @entity2 ) is limited. This study evaluated the impact of AC use and @entity1 size on outcomes using a large, nationwide @entity1 database. METHODS: The effect of AC on long-term survival among @entity0 who underwent lobectomy for margin-negative pathologic T1-2N0M0 @entity2 in the National Cancer Data Base from 2003 to 2006 was estimated using the Kaplan-Meier method. The specific @entity1 size threshold at which AC began providing benefit was estimated with multivariable Cox proportional hazards modeling. RESULTS: Overall 3,496 of 34,360 @entity0 (10.2%) who met inclusion criteria were treated with AC, although AC use increased over time from 2003, when only 2.7% of @entity0 with @entity1 less than 4 cm and 6.2% of @entity0 with @entity1 of 4 cm or larger received AC. In unadjusted survival analysis, AC was associated with a significant 5-year survival benefit for @entity0 with @entity1 less than 4 cm (74.3% vs 66.9%; P<.0001) and 4 cm or greater (64.8% vs 49.8%; P<.0001). In subanalyses of @entity0 grouped by strata of 0.5-cm increments in @entity1 size, AC was associated with a survival advantage for @entity1 sizes ranging from 3.0 to 8.5 cm. CONCLUSIONS: Use of AC among @entity0 with stage I @entity2 has increased over time but remains uncommon. The results of this study support current treatment guidelines that recommend AC use after lobectomy for stage I @entity2 larger than 4 cm. These results also suggest that AC use is associated with superior survival for @entity0 with @entity1 ranging from 3.0 to 8.5 cm in diameter.

title: Adjuvant Chemotherapy After Lobectomy for T1-2N0 XXXX : Are the Guidelines Supported?

answer: @entity2


abstract: @entity4 kinase inhibitors (TKIs) have profoundly changed the natural history of @entity5 ( @entity5 ). However, acquired resistance to @entity6 , @entity7 or @entity8 (1(st) and 2(nd) generation TKIs), due in part to BCR-ABL1 kinase mutations, has been largely described. These drugs are ineffective on the @entity10 gatekeeper substitution, which remains sensitive to 3(rd) generation TKI @entity11 . It has recently been suggested that the hematopoietic niche could protect leukemic cells from targeted therapy. In order to investigate the role of a stromal niche in mutation-related resistance, we developed a niche-based cell mutagenesis assay. For this purpose, @entity3 ( @entity2 )-exposed @entity0 cells expressing non-mutated or @entity10 -mutated BCR-ABL1 were cultured with or without @entity1 @entity1 stromal cells and in the presence of @entity6 , @entity7 , @entity8 , or @entity11 . In the assays relative to 1(st) and 2(nd) generation TKIs, which were performed on non-mutated BCR-ABL1 cells, our data highlighted the increasing efficacy of the latter, but did not reveal any substantial effect of the niche. In @entity11 assays performed on both non-mutated and @entity10 -mutated BCR-ABL1 cells, an increased number of resistant clones were observed in the presence of MS-5. Present data suggested that @entity10 mutants need either compound mutations (e.g. @entity9 / @entity10 ) or a stromal niche to escape from @entity11 . Using array-comparative genomic hybridization experiments, we found an increased number of variations (involving some recurrent chromosome regions) in clones cultured on MS-5 feeder. Overall, our study suggests that the hematopoietic niche could play a crucial role in conferring resistance to @entity11 , by providing survival signals and favoring genetic instability.

title: Modeling the influence of stromal microenvironment in the selection of @entity3 -induced BCR-ABL1 mutants by XXXX kinase inhibitors.

answer: @entity4


abstract: @entity4 kinase inhibitors (TKIs) have profoundly changed the natural history of @entity5 ( @entity5 ). However, acquired resistance to @entity6 , @entity7 or @entity8 (1(st) and 2(nd) generation TKIs), due in part to BCR-ABL1 kinase mutations, has been largely described. These drugs are ineffective on the @entity10 gatekeeper substitution, which remains sensitive to 3(rd) generation TKI @entity11 . It has recently been suggested that the hematopoietic niche could protect leukemic cells from targeted therapy. In order to investigate the role of a stromal niche in mutation-related resistance, we developed a niche-based cell mutagenesis assay. For this purpose, @entity3 ( @entity2 )-exposed @entity0 cells expressing non-mutated or @entity10 -mutated BCR-ABL1 were cultured with or without @entity1 @entity1 stromal cells and in the presence of @entity6 , @entity7 , @entity8 , or @entity11 . In the assays relative to 1(st) and 2(nd) generation TKIs, which were performed on non-mutated BCR-ABL1 cells, our data highlighted the increasing efficacy of the latter, but did not reveal any substantial effect of the niche. In @entity11 assays performed on both non-mutated and @entity10 -mutated BCR-ABL1 cells, an increased number of resistant clones were observed in the presence of MS-5. Present data suggested that @entity10 mutants need either compound mutations (e.g. @entity9 / @entity10 ) or a stromal niche to escape from @entity11 . Using array-comparative genomic hybridization experiments, we found an increased number of variations (involving some recurrent chromosome regions) in clones cultured on MS-5 feeder. Overall, our study suggests that the hematopoietic niche could play a crucial role in conferring resistance to @entity11 , by providing survival signals and favoring genetic instability.

title: Modeling the influence of stromal microenvironment in the selection of XXXX -induced BCR-ABL1 mutants by @entity4 kinase inhibitors.

answer: @entity3


abstract: Artificial @entity1 was performed in @entity2 which were then held for different periods of time. The non-operated side was used as a control. At various times from 4 to 15 days, hamsters were killed, testes were removed and weighed, single cell suspensions were prepared for flow cytometry analysis and seminiferous tubules were fixed for confocal microscopy. Using DNA staining by @entity3 or @entity4 followed by flow cytometry analysis, a marked decrease in the haploid condensed cell fraction was detected at the beginning stages of experimental cryptorchidism. In correlation with flow cytometry results, spermiogenic arrest at stages IX and X of seminiferous epithelium was detected in these animals by confocal microscopy and there were no mature forms of haploid cells in the cryptorchid testis. In the testis with more severe damage, there were almost no haploid cells in the seminiferous tubules of cryptorchid animals. In addition, a significant decrease in tetraploid cell fraction and an increase in S-phase fraction was obtained in severe cases. This may be explained by cell arrest before entrance into meiosis. Destruction of tubule structure and cell arrangement were also observed by confocal microscopy in such cases. In conclusion, flow cytometry, combined with confocal analysis, added useful information about spermatogenesis disturbances in cryptorchid testis and it may be used as diagnostic tools in other cases of @entity0 .

title: Evaluation of damage to the testicular cells of XXXX caused by experimental cryptorchidism using flow cytometry and confocal microscopy.

answer: @entity2


abstract: UNASSIGNED: Purpose: The morphologic spectrum of @entity3 extends from discrete @entity4 of the entire aortic arch. Neonates with @entity3 frequently present with @entity2 and critically reduced perfusion of the descending aorta following ductal closure. During the recent years we observed several @entity0 with @entity3 who presented beyond the neonatal period with @entity1 ( @entity1 ). We reviewed our @entity0 with @entity3 to determine whether this presentation represents an exception or is relevant for the differential diagnosis of @entity0 with @entity1 . Materials and Methods: From 1/2001 to 12/2013 74 babies with @entity3 were diagnosed in our institution. 50 @entity0 presented in the neonatal period and 24 @entity0 beyond the first month. Results: 5/74 @entity0 presented after the neonatal period with poorly contractile, dilated left ventricles. Echocardiographic detection of the @entity3 was facilitated by application of the ductal view and by Doppler interrogation of the celiac artery revealing a significantly diminished systolic flow velocity. All @entity0 underwent resection of the @entity3 and end-to-end anastomosis of  the aorta. Postoperative normalization of left ventricular function was observed within a median interval of 2 months. Conclusion: Coarctation of the aorta presenting as @entity1 accounted for 21% of our @entity0 with @entity3 who presented beyond the neonatal period and 7% of those in the first year of life. The stenosis was difficult to detect because of its distal location and normal configuration of the aortic arch. @entity3 should be included in the differential diagnosis of @entity0 with @entity1 and requires careful examination of the isthmic region in these @entity0 .

title: Pitfalls in Echocardiography: Coarctation of the Aorta Presenting as XXXX ( @entity1 ).

answer: @entity1


abstract: UNASSIGNED: Purpose: The morphologic spectrum of @entity3 extends from discrete @entity4 of the entire aortic arch. Neonates with @entity3 frequently present with @entity2 and critically reduced perfusion of the descending aorta following ductal closure. During the recent years we observed several @entity0 with @entity3 who presented beyond the neonatal period with @entity1 ( @entity1 ). We reviewed our @entity0 with @entity3 to determine whether this presentation represents an exception or is relevant for the differential diagnosis of @entity0 with @entity1 . Materials and Methods: From 1/2001 to 12/2013 74 babies with @entity3 were diagnosed in our institution. 50 @entity0 presented in the neonatal period and 24 @entity0 beyond the first month. Results: 5/74 @entity0 presented after the neonatal period with poorly contractile, dilated left ventricles. Echocardiographic detection of the @entity3 was facilitated by application of the ductal view and by Doppler interrogation of the celiac artery revealing a significantly diminished systolic flow velocity. All @entity0 underwent resection of the @entity3 and end-to-end anastomosis of  the aorta. Postoperative normalization of left ventricular function was observed within a median interval of 2 months. Conclusion: Coarctation of the aorta presenting as @entity1 accounted for 21% of our @entity0 with @entity3 who presented beyond the neonatal period and 7% of those in the first year of life. The stenosis was difficult to detect because of its distal location and normal configuration of the aortic arch. @entity3 should be included in the differential diagnosis of @entity0 with @entity1 and requires careful examination of the isthmic region in these @entity0 .

title: Pitfalls in Echocardiography: Coarctation of the Aorta Presenting as @entity1 ( XXXX ).

answer: @entity1


abstract: BACKGROUND: Percutaneous sclerotherapy is an alternative to surgery for the treatment of @entity1 (LMs). We present a large series of @entity0 undergoing sclerotherapy for macrocystic LMs with detailed visual acuity (VA) outcome data. METHODS: Data were collected prospectively in all @entity0 with macrocystic orbital LMs undergoing sclerotherapy. Sclerotherapy was performed under general anaesthesia, instilling @entity2 under imaging control. Procedures were repeated at 2-week to 6-week intervals, depending on clinical response. @entity0 underwent ophthalmological assessment, ultrasound and/or MRI before and after treatment. PRIMARY OUTCOME MEASURE: change in maximal radiological diameter of the LM. Secondary outcome measure: change in VA after treatment. RESULTS: 29 @entity0 underwent 71 procedures (1-8 procedures per @entity0 ) over 6.7   years. Mean age=7.31   years. 11 @entity0 (37.9%) had undergone previous treatment, including excision biopsy, drainage and decompression. All @entity0 presented with proptosis and/or pseudoptosis. 23 @entity0 (79.3%) had decreased VA at presentation. Average follow-up was 21.8   months (range 3-75   months). All @entity0 achieved a reduction in maximal lesion diameter of >= 50%, with complete radiological resolution in 51.7% (n=15). VA improved in 18/23 @entity0 (78.2%). Average logMAR before treatment=0.43 (SD   0.47); average after treatment=0.25 (SD   0.32); p<0.01. There was one complication (1.4%): one @entity0 required a lateral canthotomy for an intralesional haematoma 2   h after sclerotherapy. CONCLUSIONS: Sclerotherapy is a safe and highly effective treatment for orbital LMs with excellent VA outcomes. It should be considered as the first-line treatment for this condition.

title: Sclerotherapy treatment of XXXX : a large single-centre experience.

answer: @entity1


abstract: BACKGROUND: The foot fat pad (FFP) bears body weight and may become a source of foot @entity2 during aging. This study investigated the regenerative effects of autologous @entity3 ( @entity3 ) in the FFP of @entity1 . METHODS: Fat tissue was harvested from a total of 30 male @entity1 for isolation of @entity3 . The cells were cultured, adipogenic differentiation was induced for 1 week, and the @entity3 were labeled with fluorescent dye before injection. @entity3 (5 * 10(4) in 50   L of saline) were injected into the second infradigital pad in the right hindfoot of the @entity1 of origin. Saline only (50   L) was injected into the corresponding fat pad in the left hind paw of each @entity1 . @entity1 (n = 10) were euthanized at 1, 2, and 3 weeks, and the second infradigital fat pads were dissected for histologic examination. RESULTS: The fluorescence-labeled @entity3 were present in the foot pads throughout the 3-week experimental period. On histologic testing, the area of fat pad units (FPUs) in the fat pads that received AT-MSC injections was greater than that in the control fat pads. Although the thickness of septae was not changed by AT-MSC injections, the density of elastic fibers in the septae was increased in the fat pads with @entity3 . CONCLUSION: In this short-term study, the @entity3 largely survived and might have stimulated the expansion of individual FPUs and increased the density of elastic fibers in the FFP in this @entity1 model. CLINICAL RELEVANCE: These data support the development of stem cell therapies for age-associated degeneration in FFP in @entity0 .

title: Implantation of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in Foot Fat Pad in XXXX .

answer: @entity1


abstract: BACKGROUND: @entity1 is a rare but important cause of @entity3 . Current endoscopic methods used to treat @entity1 include injection, with or without thermal methods, and mechanical methods. The latter include variceal ligation and hemoclips. There are no studies comparing the outcomes of @entity7 and injection with or without thermal therapy. AIM: To report the outcomes of @entity1 treated endoscopically with @entity7 and injection with or without thermal therapy at a single institution. METHODS: @entity0 with the diagnosis of @entity1 treated endoscopically at the Carl T. Hayden VA Medical Center in Phoenix, between August 1994 and August 2002 were analyzed. Demographic data, mode of presentation, risk factors for @entity3 , hemodynamic parameters, blood transfusion requirements, endoscopic findings, details of endoscopic therapy, length of stay in ICU/hospital, complications, recurrence of @entity4 , and mortality rates were collected and compared between those receiving endoscopic band ligation (EBL group) and those receiving injection with or without thermal therapy (non-EBL group). RESULTS: Twenty-three @entity0 with @entity1 (14 in the EBL group and nine in the non-EBL group) were studied. All @entity0 were @entity0 . The mean age, hemoglobin levels on admission, and the transfusion requirements before therapy were similar in both groups. Fourteen @entity0 (eight in the EBL- and six in the non-EBL groups) presented with hematemesis and the remaining with melena. The majority of @entity1 (91.3%) were located in the stomach and two in the duodenum. Active @entity4 at the time of endoscopy was seen in 61% of cases, and immediate hemostasis was achieved with either method in 100% of @entity0 . Early rebleeding (within 72 hours of endoscopic therapy) occurred in only one @entity0 treated with @entity6 plus heater probe therapy. The length of stay in ICU was longer in the non-EBL group (6.7 days) compared with the EBL group (1.8 days) (P = 0.2). There were six deaths (three in the non-EBL group and three in the EBL group) within 30 days of the index hospitalization. The causes of death included @entity2 (n = 3), complications of @entity5 (n = 2), and @entity8 (n = 1). CONCLUSIONS: Endoscopic @entity7 is as effective as injection with or without thermal therapy in the treatment of @entity1 .

title: Outcomes of endoscopic treatment of gastroduodenal Dieulafoy's lesion with XXXX and thermal/injection therapy.

answer: @entity7


abstract: STUDY DESIGN: A prospective self-assessment analysis of a consecutive series of adult @entity0 diagnosed with @entity7 of adolescent onset or de novo @entity4 . PURPOSE: To analyze the impact that @entity7 has on @entity0 health perceptions. SUMMARY OF BACKGROUND DATA: There exists little data studying the effect @entity7 has on an adult's self-perception of health. METHODS: Inclusion criteria were: age > or =18 years, Cobb angle greater than 10 degrees, @entity1 , no prior surgery (spine), and complete records. Each @entity0 completed the standard Short Form-36 (SF-36) questionnaire. For each @entity0 , radiographic and clinical data were evaluated. After all data were collected, the mean, standard deviation (SD), and true N values of the Cobb angle were calculated. This study population was then divided into two groups: @entity0 with a Cobb angle greater than 10 degrees and @entity0 with a Cobb angle greater than 20 degrees. Comparison of the SF-36 data for @entity7 @entity0 with the United States general population, the United States general population ages 55-64, and @entity0 with @entity2 and @entity8 was undertaken. RESULTS: The mean age for the @entity0 in this study was 63 years of age; 22 @entity0 were diagnosed as having @entity7 of adolescent onset and 27 @entity0 had de novo @entity4 . The Cobb angle in this study group was found to be greater than 20 degrees in 41 @entity0 ; of these @entity0 , 19 @entity0 had a diagnosis of @entity7 of adolescent onset and 22 @entity0 had a diagnosis of de novo @entity4 . Taken as a whole, the @entity0 in this study averaged scores much lower than the norms for both the general U.S. population in all 8 categories and the U.S. population for ages 55 to 64 in 7 out of 8 categories of the SF-36 questionnaire. Additionally, @entity0 with @entity7 also showed lower scores compared to that of the norms found of @entity0 with comorbid conditions: @entity6 /sciatica with @entity2 in seven of the eight categories: physical functioning, role physical, bodily @entity3 , general health, vitality, social functioning, role emotional, and mental health. Of the radiographic parameters analyzed, @entity5 revealed a significant correlation with social function: P = 0.018; role emotional: P = 0.038; and overall general health: P = 0.05. The other radiographic parameters did not reveal statistically significant correlation to the calculated SF-36 scores. CONCLUSION: Our data clearly demonstrate the impact that @entity7 has on a @entity0 's perception of health. The severity of this impact is strikingly apparent in the SF-36 scores when compared to benchmark data on @entity0 with comorbid conditions such as @entity6 and @entity2 . It is our conclusion that @entity7 is becoming a medical condition of significant impact, affecting the fastest growing section of our society to a previously unrecognized degree.

title: XXXX : a health assessment analysis by SF-36.

answer: @entity7


abstract: OBJECTIVES: Evaluation of double cross plasty for management of obstructive or non obstructive transverse @entity3 . METHODS: 13 @entity0 presented either as cryptomenorrhoea or as @entity1 / @entity4 were diagnosed to have transverse @entity3 . They were subjected to double cross plasty and were subsequently followed up for period of two years. RESULTS: 13 @entity0 presented either as cryptomenorrhoea or @entity1 / @entity4 . Nine @entity0 had transverse @entity3 at low level, three at midlevel, and one had high-level septum. The thickness of septum was 1-3 cms in 12 @entity0 . Double cross plasty was performed in all @entity0 . One @entity0 with high @entity3 which was thick needed bilateral labial flaps. All @entity0 were followed up to period of 2  years and none had @entity2 . Three @entity0 had pregnancies with vaginal delivery in two of them. CONCLUSION: Double cross plasty for management of transverse @entity3 is a better technique compared with currently used surgical methods. In our series, it did not cause @entity2 and some of our @entity0 were able to deliver vaginally.

title: Double Cross Plasty for Management of Transverse XXXX : A 20-Year Retrospective Review of Our Experience.

answer: @entity3


abstract: Cyclin-dependent kinase inhibitors @entity10 ( @entity10 ) and @entity9 ( @entity9 ), encoded by the @entity10 loci, play an important role in negative regulation of the cell cycle. Furthermore, @entity11 (ARF) also encoded by the @entity10 locus, has been shown to regulate positively the @entity4 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in @entity0 @entity1 . In myeloid cells, @entity9 ( @entity9 ) mRNA is upregulated during cytokine-induced @entity3 , and hypermethylation of the @entity9 ( @entity9 ) gene promoter region is a common event in @entity8 . In the present study, we examined @entity2 monocyte/macrophage @entity1 with deregulated c-myc for evidence of Ink4 gene inactivation. @entity9 ( @entity9 ) mRNA and protein were detected in the majority of @entity7 , and @entity10 ( @entity10 ) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the @entity1 indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of @entity9 ( @entity9 ) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these @entity1 . An examination of @entity11 (Arf) exons revealed deletions of the gene in up to 94% of the @entity1 . Since this gene shares exon 2 with @entity10 ( @entity10 ), it is often difficult to determine which gene is the relevant @entity1 suppressor. However, the loss of only the @entity11 was observed in a @entity1 that had normal @entity10 ( @entity10 ) protein expression. In addition, the @entity11 (Arf)-specific exon was deleted in another @entity1 that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing @entity5 . These data overall supports the hypothesis that the critical inactivation event in these @entity6 is elimination of @entity11 (Arf), and not Ink4 function.

title: Consistent inactivation of @entity11 but not XXXX ( @entity9 ) in @entity2 myeloid cells transformed in vivo by deregulated c-Myc.

answer: @entity9


abstract: Cyclin-dependent kinase inhibitors @entity10 ( @entity10 ) and @entity9 ( @entity9 ), encoded by the @entity10 loci, play an important role in negative regulation of the cell cycle. Furthermore, @entity11 (ARF) also encoded by the @entity10 locus, has been shown to regulate positively the @entity4 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in @entity0 @entity1 . In myeloid cells, @entity9 ( @entity9 ) mRNA is upregulated during cytokine-induced @entity3 , and hypermethylation of the @entity9 ( @entity9 ) gene promoter region is a common event in @entity8 . In the present study, we examined @entity2 monocyte/macrophage @entity1 with deregulated c-myc for evidence of Ink4 gene inactivation. @entity9 ( @entity9 ) mRNA and protein were detected in the majority of @entity7 , and @entity10 ( @entity10 ) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the @entity1 indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of @entity9 ( @entity9 ) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these @entity1 . An examination of @entity11 (Arf) exons revealed deletions of the gene in up to 94% of the @entity1 . Since this gene shares exon 2 with @entity10 ( @entity10 ), it is often difficult to determine which gene is the relevant @entity1 suppressor. However, the loss of only the @entity11 was observed in a @entity1 that had normal @entity10 ( @entity10 ) protein expression. In addition, the @entity11 (Arf)-specific exon was deleted in another @entity1 that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing @entity5 . These data overall supports the hypothesis that the critical inactivation event in these @entity6 is elimination of @entity11 (Arf), and not Ink4 function.

title: Consistent inactivation of @entity11 but not @entity9 ( XXXX ) in @entity2 myeloid cells transformed in vivo by deregulated c-Myc.

answer: @entity9


abstract: Cyclin-dependent kinase inhibitors @entity10 ( @entity10 ) and @entity9 ( @entity9 ), encoded by the @entity10 loci, play an important role in negative regulation of the cell cycle. Furthermore, @entity11 (ARF) also encoded by the @entity10 locus, has been shown to regulate positively the @entity4 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in @entity0 @entity1 . In myeloid cells, @entity9 ( @entity9 ) mRNA is upregulated during cytokine-induced @entity3 , and hypermethylation of the @entity9 ( @entity9 ) gene promoter region is a common event in @entity8 . In the present study, we examined @entity2 monocyte/macrophage @entity1 with deregulated c-myc for evidence of Ink4 gene inactivation. @entity9 ( @entity9 ) mRNA and protein were detected in the majority of @entity7 , and @entity10 ( @entity10 ) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the @entity1 indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of @entity9 ( @entity9 ) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these @entity1 . An examination of @entity11 (Arf) exons revealed deletions of the gene in up to 94% of the @entity1 . Since this gene shares exon 2 with @entity10 ( @entity10 ), it is often difficult to determine which gene is the relevant @entity1 suppressor. However, the loss of only the @entity11 was observed in a @entity1 that had normal @entity10 ( @entity10 ) protein expression. In addition, the @entity11 (Arf)-specific exon was deleted in another @entity1 that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing @entity5 . These data overall supports the hypothesis that the critical inactivation event in these @entity6 is elimination of @entity11 (Arf), and not Ink4 function.

title: Consistent inactivation of XXXX but not @entity9 ( @entity9 ) in @entity2 myeloid cells transformed in vivo by deregulated c-Myc.

answer: @entity11


abstract: Cyclin-dependent kinase inhibitors @entity10 ( @entity10 ) and @entity9 ( @entity9 ), encoded by the @entity10 loci, play an important role in negative regulation of the cell cycle. Furthermore, @entity11 (ARF) also encoded by the @entity10 locus, has been shown to regulate positively the @entity4 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in @entity0 @entity1 . In myeloid cells, @entity9 ( @entity9 ) mRNA is upregulated during cytokine-induced @entity3 , and hypermethylation of the @entity9 ( @entity9 ) gene promoter region is a common event in @entity8 . In the present study, we examined @entity2 monocyte/macrophage @entity1 with deregulated c-myc for evidence of Ink4 gene inactivation. @entity9 ( @entity9 ) mRNA and protein were detected in the majority of @entity7 , and @entity10 ( @entity10 ) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the @entity1 indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of @entity9 ( @entity9 ) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these @entity1 . An examination of @entity11 (Arf) exons revealed deletions of the gene in up to 94% of the @entity1 . Since this gene shares exon 2 with @entity10 ( @entity10 ), it is often difficult to determine which gene is the relevant @entity1 suppressor. However, the loss of only the @entity11 was observed in a @entity1 that had normal @entity10 ( @entity10 ) protein expression. In addition, the @entity11 (Arf)-specific exon was deleted in another @entity1 that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing @entity5 . These data overall supports the hypothesis that the critical inactivation event in these @entity6 is elimination of @entity11 (Arf), and not Ink4 function.

title: Consistent inactivation of @entity11 but not @entity9 ( @entity9 ) in XXXX myeloid cells transformed in vivo by deregulated c-Myc.

answer: @entity2


abstract: The effects of @entity5 , a converting enzyme inhibitor (CEI), on left ventricular (LV) diastolic stiffness and coronary vascular resistance (CVR), were studied with an isolated heart preparation in 15-month-old spontaneously @entity1 @entity0 (SHR). The @entity1 animals were treated for 3 months with @entity5 (0.3 mg/kg/day) (SHRT), and compared with untreated age-matched @entity0 -Kyoto @entity0 (WKY) and SHR. @entity5 treatment resulted in 15% diminution in blood pressure (BP). In contrast, it completely normalized left ventricular (LV) weight. Untreated SHR, as compared with WKY, had a dilated LV and increased diastolic tissue stiffness. @entity5 had no effect on either chamber or tissue stiffness. Five-minute @entity2 resulted in the same dramatic increase in chamber stiffness in every experimental group. During @entity2 , as during normoxia, tissue stiffness was still greater in SHR than in WKY. A major effect of CEI was to normalize the tissue stiffness of SHR under @entity2 . Coronary vascular resistance (CVR) was increased in SHR as compared with WKY. @entity5 improves CVR and significantly shifts the coronary pressure flow curve to the dilatory side. Both collagen concentration (approximately 2 mg/g) and the content in slow V3 myosin isoform, used as biologic markers of cardiac senescence, were the same in the three experimental groups, but higher than in young hearts. @entity5 had no effect on these parameters. In semisenescent SHR, despite having rather slight effect on arterial pressure, @entity5 completely normalized LV weight. In addition, collagen content and its physiologic counterpart, tissue stiffness, were unaffected by 3-month treatment with @entity5 . Nevertheless, the @entity2 -induced increase in LV tissue stiffness was improved by @entity5 in parallel with reduction in @entity4 ( @entity3 ).

title: Regression of @entity4 by converting enzyme inhibition in 12-15-month-old spontaneously @entity1 @entity0 : effects on coronary resistance and ventricular compliance in normoxia and XXXX .

answer: @entity2


abstract: The effects of @entity5 , a converting enzyme inhibitor (CEI), on left ventricular (LV) diastolic stiffness and coronary vascular resistance (CVR), were studied with an isolated heart preparation in 15-month-old spontaneously @entity1 @entity0 (SHR). The @entity1 animals were treated for 3 months with @entity5 (0.3 mg/kg/day) (SHRT), and compared with untreated age-matched @entity0 -Kyoto @entity0 (WKY) and SHR. @entity5 treatment resulted in 15% diminution in blood pressure (BP). In contrast, it completely normalized left ventricular (LV) weight. Untreated SHR, as compared with WKY, had a dilated LV and increased diastolic tissue stiffness. @entity5 had no effect on either chamber or tissue stiffness. Five-minute @entity2 resulted in the same dramatic increase in chamber stiffness in every experimental group. During @entity2 , as during normoxia, tissue stiffness was still greater in SHR than in WKY. A major effect of CEI was to normalize the tissue stiffness of SHR under @entity2 . Coronary vascular resistance (CVR) was increased in SHR as compared with WKY. @entity5 improves CVR and significantly shifts the coronary pressure flow curve to the dilatory side. Both collagen concentration (approximately 2 mg/g) and the content in slow V3 myosin isoform, used as biologic markers of cardiac senescence, were the same in the three experimental groups, but higher than in young hearts. @entity5 had no effect on these parameters. In semisenescent SHR, despite having rather slight effect on arterial pressure, @entity5 completely normalized LV weight. In addition, collagen content and its physiologic counterpart, tissue stiffness, were unaffected by 3-month treatment with @entity5 . Nevertheless, the @entity2 -induced increase in LV tissue stiffness was improved by @entity5 in parallel with reduction in @entity4 ( @entity3 ).

title: Regression of XXXX by converting enzyme inhibition in 12-15-month-old spontaneously @entity1 @entity0 : effects on coronary resistance and ventricular compliance in normoxia and @entity2 .

answer: @entity4


abstract: The effects of @entity5 , a converting enzyme inhibitor (CEI), on left ventricular (LV) diastolic stiffness and coronary vascular resistance (CVR), were studied with an isolated heart preparation in 15-month-old spontaneously @entity1 @entity0 (SHR). The @entity1 animals were treated for 3 months with @entity5 (0.3 mg/kg/day) (SHRT), and compared with untreated age-matched @entity0 -Kyoto @entity0 (WKY) and SHR. @entity5 treatment resulted in 15% diminution in blood pressure (BP). In contrast, it completely normalized left ventricular (LV) weight. Untreated SHR, as compared with WKY, had a dilated LV and increased diastolic tissue stiffness. @entity5 had no effect on either chamber or tissue stiffness. Five-minute @entity2 resulted in the same dramatic increase in chamber stiffness in every experimental group. During @entity2 , as during normoxia, tissue stiffness was still greater in SHR than in WKY. A major effect of CEI was to normalize the tissue stiffness of SHR under @entity2 . Coronary vascular resistance (CVR) was increased in SHR as compared with WKY. @entity5 improves CVR and significantly shifts the coronary pressure flow curve to the dilatory side. Both collagen concentration (approximately 2 mg/g) and the content in slow V3 myosin isoform, used as biologic markers of cardiac senescence, were the same in the three experimental groups, but higher than in young hearts. @entity5 had no effect on these parameters. In semisenescent SHR, despite having rather slight effect on arterial pressure, @entity5 completely normalized LV weight. In addition, collagen content and its physiologic counterpart, tissue stiffness, were unaffected by 3-month treatment with @entity5 . Nevertheless, the @entity2 -induced increase in LV tissue stiffness was improved by @entity5 in parallel with reduction in @entity4 ( @entity3 ).

title: Regression of @entity4 by converting enzyme inhibition in 12-15-month-old spontaneously XXXX @entity0 : effects on coronary resistance and ventricular compliance in normoxia and @entity2 .

answer: @entity1


abstract: The effects of @entity5 , a converting enzyme inhibitor (CEI), on left ventricular (LV) diastolic stiffness and coronary vascular resistance (CVR), were studied with an isolated heart preparation in 15-month-old spontaneously @entity1 @entity0 (SHR). The @entity1 animals were treated for 3 months with @entity5 (0.3 mg/kg/day) (SHRT), and compared with untreated age-matched @entity0 -Kyoto @entity0 (WKY) and SHR. @entity5 treatment resulted in 15% diminution in blood pressure (BP). In contrast, it completely normalized left ventricular (LV) weight. Untreated SHR, as compared with WKY, had a dilated LV and increased diastolic tissue stiffness. @entity5 had no effect on either chamber or tissue stiffness. Five-minute @entity2 resulted in the same dramatic increase in chamber stiffness in every experimental group. During @entity2 , as during normoxia, tissue stiffness was still greater in SHR than in WKY. A major effect of CEI was to normalize the tissue stiffness of SHR under @entity2 . Coronary vascular resistance (CVR) was increased in SHR as compared with WKY. @entity5 improves CVR and significantly shifts the coronary pressure flow curve to the dilatory side. Both collagen concentration (approximately 2 mg/g) and the content in slow V3 myosin isoform, used as biologic markers of cardiac senescence, were the same in the three experimental groups, but higher than in young hearts. @entity5 had no effect on these parameters. In semisenescent SHR, despite having rather slight effect on arterial pressure, @entity5 completely normalized LV weight. In addition, collagen content and its physiologic counterpart, tissue stiffness, were unaffected by 3-month treatment with @entity5 . Nevertheless, the @entity2 -induced increase in LV tissue stiffness was improved by @entity5 in parallel with reduction in @entity4 ( @entity3 ).

title: Regression of @entity4 by converting enzyme inhibition in 12-15-month-old spontaneously @entity1 XXXX : effects on coronary resistance and ventricular compliance in normoxia and @entity2 .

answer: @entity0


abstract: STUDY OBJECTIVES: To evaluate the rate of intrauterine adhesions after hysteroscopic resection of @entity1 areas and the efficacy of combined treatment. DESIGN: Observational retrospective study. SETTING: @entity0 affected by @entity5 or early stage @entity3 . @entity0 : Twenty-three @entity0 , up to 45 years of age. INTERVENTION: Conservative treatment based on hysteroscopic resection of @entity1 areas and subsequent therapy with @entity7 160 mg/day. METHODS AND MAIN RESULTS: Approximately 5% of @entity3 ( @entity3 ) are diagnosed in @entity0 younger than 40 years old, usually with a good prognosis. From 2010 to 2014, 23 @entity0 , up to age 45 years, who were affected by @entity3 ( @entity3 ) grade 1 or @entity4 ( @entity4 ) and who wished to preserve fertility, underwent conservative treatment based on hysteroscopic resection of the @entity1 areas and subsequent therapy with @entity7 160 mg/day. Data with regard to age, body mass index, symptoms, history of @entity2 , and previous assisted reproductive technologies attempts, obstetrics history, previous diagnosis of intrauterine sinechiae, hysteroscopic findings, duration of therapy, follow-up reports, and reproductive outcomes were collected and analyzed. Of the 23 @entity0 enrolled in the study, 3 @entity0 (13%) presented with an endometrioid @entity3 grade 1, and 20 @entity0 (87%) had @entity4 . Twelve @entity0 (52.2%) had complete remission after 3 months of progestin therapy, 9 @entity0 (39.1%) had a complete remission after 6 months, and 2 (8.7%) @entity0 had remission after 9 months. Six @entity0 underwent a second hysteroscopic resection. The 3 @entity0 with an initial diagnosis of @entity3 had complete remission after a mean of 4 months of high-dose progestin therapy; in @entity0 with @entity4 , remission occurred after a mean of 3 months. In all @entity0 , intrauterine adhesions were not detected at any follow-up diagnostic hysteroscopy. After a median follow-up time of 25 months (range 8-37), we registered 1 (4.3%) relapse of disease. A total of 7 pregnancies in 6 @entity0 were counted, after an average time of 7.4 months (range 3-13 months) after the end of @entity6 therapy. CONCLUSIONS: Hysteroscopic resection of @entity1 areas before high dosage progestin therapy seems to be a safe and effective approach in the management of @entity4 and in @entity0 with early @entity3 who wish to preserve fertility.

title: Hysteroscopic Resection in Fertility-Sparing Surgery for XXXX and Endometrial Cancer: Safety and Efficacy.

answer: @entity4


abstract: Increasing evidence suggests that @entity7 treatment may represent a potential risk in @entity0 exposed to cardiac surgery. Conversely, @entity7 has been suggested to be beneficial as an additive to cardioplegic solutions, but its use has not been tried in vivo. We evaluated hemodynamic, ECG, and possible toxicologic effects of @entity7 when added to the cardioplegic solution. @entity6 weighing (70 +/- 2 kg, n = 24) were exposed to cardiopulmonary bypass (CPB) and hypothermic @entity5 for 1 h with @entity3 ( @entity3 ) or St. Thomas' Hospital (St. Th.) cardioplegic solution. @entity7 or the solvent was added to the solutions. Only @entity6 receiving the lowest dose of @entity7 (0.028 mg/g tissue) could be weaned from bypass. Higher doses resulted in graded @entity4 without recovery of electrical activity. Electron microscopy showed severely disintegrated myocytes and swollen mitochondria in @entity7 -exposed hearts. No changes in equilibrium binding characteristics were observed for beta-adrenoceptors, whereas maximum binding capacity (MBC) and receptor affinity for voltage-operated @entity2 channels were dose-dependently decreased (mean 73%, p < 0.0005; 105%; p < 0.05). @entity2 paradoxlike findings similar to those in @entity6 were inducible in isolated, in vitro perfused @entity1 heart exposed to normothermic or hypothermic @entity5 with @entity3 and @entity7 . This model was therefore used to evaluate whether the observed @entity4 was associated with excessive tissue @entity2 accumulation. Addition of @entity7 to @entity3 was associated with a significant increase in 45 @entity2 content in the heart, irrespective of temperature. Only 2 of 13 hearts recovered some degree of mechanical activity during reperfusion. When @entity8 (an antiarrhythmic drug with membrane-stabilizing properties, an effect that is potentiated by @entity7 ) was removed from @entity3 , 45 @entity2 accumulation did not differ from that in controls and mechanical activity recovered fully in 7 of 8 hearts. In conclusion, @entity7 added to @entity2 -free as well as @entity2 -containing cardioplegic solutions led to dose-dependent @entity4 at reperfusion, irrespective of temperature. In parallel with clinical features was a reduction in maximum binding capacity and a decrease in affinity for the @entity2 channel antagonist. Removal of @entity8 from @entity3 prevented excessive @entity2 accumulation and mechanical deterioration in isolated heart. We hypothesize that @entity7 administered under the conditions described may change the configuration of the @entity2 channel, rendering it more permeable to @entity2 . Pharmacologic interaction between @entity7 and @entity8 apparently is at least partly responsible for the increased @entity2 uptake and the stone-heart phenomenon during reperfusion.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Dose-dependent cardiotoxic effect of @entity7 in cardioplegic solutions correlates with loss of dihydropyridine binding sites: in vitro evidence for a potentially lethal interaction with XXXX .

answer: @entity8


abstract: Increasing evidence suggests that @entity7 treatment may represent a potential risk in @entity0 exposed to cardiac surgery. Conversely, @entity7 has been suggested to be beneficial as an additive to cardioplegic solutions, but its use has not been tried in vivo. We evaluated hemodynamic, ECG, and possible toxicologic effects of @entity7 when added to the cardioplegic solution. @entity6 weighing (70 +/- 2 kg, n = 24) were exposed to cardiopulmonary bypass (CPB) and hypothermic @entity5 for 1 h with @entity3 ( @entity3 ) or St. Thomas' Hospital (St. Th.) cardioplegic solution. @entity7 or the solvent was added to the solutions. Only @entity6 receiving the lowest dose of @entity7 (0.028 mg/g tissue) could be weaned from bypass. Higher doses resulted in graded @entity4 without recovery of electrical activity. Electron microscopy showed severely disintegrated myocytes and swollen mitochondria in @entity7 -exposed hearts. No changes in equilibrium binding characteristics were observed for beta-adrenoceptors, whereas maximum binding capacity (MBC) and receptor affinity for voltage-operated @entity2 channels were dose-dependently decreased (mean 73%, p < 0.0005; 105%; p < 0.05). @entity2 paradoxlike findings similar to those in @entity6 were inducible in isolated, in vitro perfused @entity1 heart exposed to normothermic or hypothermic @entity5 with @entity3 and @entity7 . This model was therefore used to evaluate whether the observed @entity4 was associated with excessive tissue @entity2 accumulation. Addition of @entity7 to @entity3 was associated with a significant increase in 45 @entity2 content in the heart, irrespective of temperature. Only 2 of 13 hearts recovered some degree of mechanical activity during reperfusion. When @entity8 (an antiarrhythmic drug with membrane-stabilizing properties, an effect that is potentiated by @entity7 ) was removed from @entity3 , 45 @entity2 accumulation did not differ from that in controls and mechanical activity recovered fully in 7 of 8 hearts. In conclusion, @entity7 added to @entity2 -free as well as @entity2 -containing cardioplegic solutions led to dose-dependent @entity4 at reperfusion, irrespective of temperature. In parallel with clinical features was a reduction in maximum binding capacity and a decrease in affinity for the @entity2 channel antagonist. Removal of @entity8 from @entity3 prevented excessive @entity2 accumulation and mechanical deterioration in isolated heart. We hypothesize that @entity7 administered under the conditions described may change the configuration of the @entity2 channel, rendering it more permeable to @entity2 . Pharmacologic interaction between @entity7 and @entity8 apparently is at least partly responsible for the increased @entity2 uptake and the stone-heart phenomenon during reperfusion.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Dose-dependent cardiotoxic effect of XXXX in cardioplegic solutions correlates with loss of dihydropyridine binding sites: in vitro evidence for a potentially lethal interaction with @entity8 .

answer: @entity7